Cargando…
Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model
BACKGROUND: Influenza epidemics significantly weight on the Brazilian healthcare system and its society. Public health authorities have progressively expanded recommendations for vaccination against influenza, particularly to the pediatric population. However, the potential mismatch between the triv...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487874/ https://www.ncbi.nlm.nih.gov/pubmed/32907562 http://dx.doi.org/10.1186/s12889-020-09409-7 |
_version_ | 1783581578285285376 |
---|---|
author | Crépey, Pascal Boiron, Louis Araujo, Rafael Rodrigo Lopez, Juan Guillermo Petitjean, Audrey de Albuquerque Luna, Expedito José |
author_facet | Crépey, Pascal Boiron, Louis Araujo, Rafael Rodrigo Lopez, Juan Guillermo Petitjean, Audrey de Albuquerque Luna, Expedito José |
author_sort | Crépey, Pascal |
collection | PubMed |
description | BACKGROUND: Influenza epidemics significantly weight on the Brazilian healthcare system and its society. Public health authorities have progressively expanded recommendations for vaccination against influenza, particularly to the pediatric population. However, the potential mismatch between the trivalent influenza vaccine (TIV) strains and those circulating during the season remains an issue. Quadrivalent vaccines improves vaccines effectiveness by preventing any potential mismatch on influenza B lineages. METHODS: We evaluate the public health and economic benefits of the switch from TIV to QIV for the pediatric influenza recommendation (6mo-5yo) by using a dynamic epidemiological model able to consider the indirect impact of vaccination. Results of the epidemiological model are then imputed in a health-economic model adapted to the Brazilian context. We perform deterministic and probabilistic sensitivity analysis to account for both epidemiological and economical sources of uncertainty. RESULTS: Our results show that switching from TIV to QIV in the Brazilian pediatric population would prevent 406,600 symptomatic cases, 11,300 hospitalizations and almost 400 deaths by influenza season. This strategy would save 3400 life-years yearly for an incremental direct cost of R$169 million per year, down to R$86 million from a societal perspective. Incremental cost-effectiveness ratios for the switch would be R$49,700 per life-year saved and R$26,800 per quality-adjusted life-year gained from a public payer perspective, and even more cost-effective from a societal perspective. Our results are qualitatively similar in our sensitivity analysis. CONCLUSIONS: Our analysis shows that switching from TIV to QIV to protect children aged 6mo to 5yo in the Brazilian influenza epidemiological context could have a strong public health impact and represent a cost-effective strategy from a public payer perspective, and a highly cost-effective one from a societal perspective. |
format | Online Article Text |
id | pubmed-7487874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74878742020-09-16 Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model Crépey, Pascal Boiron, Louis Araujo, Rafael Rodrigo Lopez, Juan Guillermo Petitjean, Audrey de Albuquerque Luna, Expedito José BMC Public Health Research Article BACKGROUND: Influenza epidemics significantly weight on the Brazilian healthcare system and its society. Public health authorities have progressively expanded recommendations for vaccination against influenza, particularly to the pediatric population. However, the potential mismatch between the trivalent influenza vaccine (TIV) strains and those circulating during the season remains an issue. Quadrivalent vaccines improves vaccines effectiveness by preventing any potential mismatch on influenza B lineages. METHODS: We evaluate the public health and economic benefits of the switch from TIV to QIV for the pediatric influenza recommendation (6mo-5yo) by using a dynamic epidemiological model able to consider the indirect impact of vaccination. Results of the epidemiological model are then imputed in a health-economic model adapted to the Brazilian context. We perform deterministic and probabilistic sensitivity analysis to account for both epidemiological and economical sources of uncertainty. RESULTS: Our results show that switching from TIV to QIV in the Brazilian pediatric population would prevent 406,600 symptomatic cases, 11,300 hospitalizations and almost 400 deaths by influenza season. This strategy would save 3400 life-years yearly for an incremental direct cost of R$169 million per year, down to R$86 million from a societal perspective. Incremental cost-effectiveness ratios for the switch would be R$49,700 per life-year saved and R$26,800 per quality-adjusted life-year gained from a public payer perspective, and even more cost-effective from a societal perspective. Our results are qualitatively similar in our sensitivity analysis. CONCLUSIONS: Our analysis shows that switching from TIV to QIV to protect children aged 6mo to 5yo in the Brazilian influenza epidemiological context could have a strong public health impact and represent a cost-effective strategy from a public payer perspective, and a highly cost-effective one from a societal perspective. BioMed Central 2020-09-09 /pmc/articles/PMC7487874/ /pubmed/32907562 http://dx.doi.org/10.1186/s12889-020-09409-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Crépey, Pascal Boiron, Louis Araujo, Rafael Rodrigo Lopez, Juan Guillermo Petitjean, Audrey de Albuquerque Luna, Expedito José Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model |
title | Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model |
title_full | Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model |
title_fullStr | Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model |
title_full_unstemmed | Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model |
title_short | Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model |
title_sort | impact of quadrivalent influenza vaccines in brazil: a cost-effectiveness analysis using an influenza transmission model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487874/ https://www.ncbi.nlm.nih.gov/pubmed/32907562 http://dx.doi.org/10.1186/s12889-020-09409-7 |
work_keys_str_mv | AT crepeypascal impactofquadrivalentinfluenzavaccinesinbrazilacosteffectivenessanalysisusinganinfluenzatransmissionmodel AT boironlouis impactofquadrivalentinfluenzavaccinesinbrazilacosteffectivenessanalysisusinganinfluenzatransmissionmodel AT araujorafaelrodrigo impactofquadrivalentinfluenzavaccinesinbrazilacosteffectivenessanalysisusinganinfluenzatransmissionmodel AT lopezjuanguillermo impactofquadrivalentinfluenzavaccinesinbrazilacosteffectivenessanalysisusinganinfluenzatransmissionmodel AT petitjeanaudrey impactofquadrivalentinfluenzavaccinesinbrazilacosteffectivenessanalysisusinganinfluenzatransmissionmodel AT dealbuquerquelunaexpeditojose impactofquadrivalentinfluenzavaccinesinbrazilacosteffectivenessanalysisusinganinfluenzatransmissionmodel |